Prenetics Global (NASDAQ:PRE) Research Coverage Started at Roth Mkm

Roth Mkm initiated coverage on shares of Prenetics Global (NASDAQ:PRE) in a research note issued to investors on Wednesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $36.00 price target on the stock.

Several other equities analysts have also issued reports on PRE. Wall Street Zen upgraded Prenetics Global from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. Cantor Fitzgerald boosted their price objective on shares of Prenetics Global from $26.00 to $32.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Prenetics Global currently has a consensus rating of “Hold” and an average target price of $34.00.

Prenetics Global Stock Up 4.8%

NASDAQ:PRE opened at $21.97 on Wednesday. The stock’s fifty day simple moving average is $17.26 and its 200-day simple moving average is $13.56. The firm has a market capitalization of $369.76 million, a P/E ratio of -10.82 and a beta of 0.35. Prenetics Global has a 12-month low of $3.09 and a 12-month high of $22.86.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP bought a new stake in shares of Prenetics Global during the fourth quarter worth $788,000. Hudson Bay Capital Management LP acquired a new position in Prenetics Global in the 4th quarter worth $296,000. Wells Fargo & Company MN bought a new position in Prenetics Global during the 4th quarter worth about $47,000. Jane Street Group LLC acquired a new stake in shares of Prenetics Global in the 4th quarter valued at about $1,302,000. Finally, T3 Companies LLC acquired a new stake in shares of Prenetics Global in the 4th quarter valued at about $170,000. Institutional investors and hedge funds own 25.01% of the company’s stock.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.